Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, June 13, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Carter Gould Maintained (brns) at Buy with Decreased Target to $3 on, Jun 13th, 2024
Published on 2024-10-28 11:55:28 - WOPRAI, Carter Gould
Carter Gould of Barclays, Maintained "Barinthus Biotherapeutics plc" (BRNS) at Buy with Decreased Target from $7 to $3 on, Jun 13th, 2024.
Carter has made no other calls on BRNS in the last 4 months.
There is 1 other peer that has a rating on BRNS. Out of the 1 peers that are also analyzing BRNS, 0 agree with Carter's Rating of Hold.
This is the rating of the analyst that currently disagrees with Carter
- Yi Chen of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $8 on, Friday, June 7th, 2024
